Non Hodgkin Lymphoma Clinical Trial
A Safety and Preliminary Efficacy Study of CC-99282, Alone and in Combination With Anti-lymphoma Agents in Participants With Relapsed or Refractory Non-Hodgkin Lymphomas (R/R NHL)
Summary
The purpose of this study is to evaluate the safety, tolerability, and preliminary efficacy of CC-99282 alone and in combination with anti-lymphoma agents in participants with relapsed or refractory non-Hodgkin’s lymphomas.
Full Description
Participants with relapsed or refractory non-Hodgkin’s lymphomas (R/R NHL) who have failed at least 2 lines of therapy (or have received at least one prior line of standard therapy and are not eligible for any other therapy).
The dose escalation will evaluate the safety and tolerability of escalating doses of CC-99282 in relapsed or refractory diffuse large B-cell lymphoma (R/R DLBCL) and/or relapsed or refractory follicular lymphoma (R/R FL) participants to determine the maximum tolerated dose (MTD) of CC-99282 as monotherapy.
The dose expansion will further evaluate the safety and preliminary efficacy of single agent CC-99282 or the safety and preliminary efficacy of CC-99282 in combination with anti-lymphoma agents in participants with R/R DLBCL and NHL.
Part B Cohort B will further evaluate the potential effects of food on the PK and safety of CC-99282.
Eligibility Criteria
Inclusion Criteria:
History of Non-Hodgkin’s Lymphoma (NHL) with relapsed or refractory disease
Has an Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1 or 2
Exclusion Criteria:
Life expectancy ≤ 2 months
Received prior systemic anti-cancer treatment (approved or investigational) ≤ 5 half-lives or 4 weeks prior to starting CC-99282, whichever is shorter
Is on chronic systemic immunosuppressive therapy or corticosteroids or has clinically significant graft-versus-host disease (GVHD)
Impaired cardiac function or clinically significant cardiac disease
Other protocol-defined inclusion/exclusion criteria apply
Check Your Eligibility
Let’s see if you might be eligible for this study.
What is your age and gender ?
There are 85 Locations for this study
La Jolla California, 92093, United States
Orange California, 92848, United States
Whittier California, 90603, United States
Overland Park Kansas, 66210, United States
Overland Park Kansas, 66210, United States More Info
Baltimore Maryland, 21201, United States
Rochester Minnesota, 55905, United States
Saint Louis Missouri, 63110, United States
Hackensack New Jersey, 07601, United States
Mineola New York, 11501, United States
Ciudad autónoma de Buenos Aires Buenos Aires, 1280, Argentina
Buenos Aires , C1426, Argentina
Cordoba , 5016, Argentina
Salzburg , 5020, Austria
St. Polten , 3100, Austria
Vienna , 1090, Austria
Edegem , 2650, Belgium
Leuven , 3000, Belgium
Leuven , 3000, Belgium
Sao Paulo Sp, 05651, Brazil More Info
Contact
Edmonton Alberta, T6G1Z, Canada
Santiago RM, 75609, Chile More Info
Contact
Santiago , 75910, Chile
Santiago , 838-0, Chile
Beijing Beijing, 10002, China More Info
Contact
Xiamen Fujian, 36100, China
Haerbin Heilongjiang, 15008, China
Tianjin Tianjin, 30006, China More Info
Contact
Hangzhou Zhejiang, 31005, China
Guangzhou , 51051, China
Bordeaux , 33076, France More Info
Montpellier CEDEX 5 , 34295, France
Ramat Gan , 52621, Israel More Info
Rozzano , 20089, Italy
Verona , 37134, Italy
Seoul , 06591, Korea, Republic of More Info
Madrid , 28040, Spain More Info
Contact
Belfast Northern Ireland , BT9 7, United Kingdom
Belfast Northern Ireland , BT9 7, United Kingdom
Edinburgh Scotland , EH4 2, United Kingdom More Info
Contact
How clear is this clinincal trial information?
